Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Smith on Frontline Treatment Options in MCL

May 14th 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Dr. Fenske on the Utility of Next-Generation BTK Inhibitors in MCL

May 13th 2020

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCL

May 13th 2020

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Dr. Wang on the Evolution of Treatment in MCL

May 13th 2020

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 13th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Gerson on Clinical Trial Accrual in MCL

May 13th 2020

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 12th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Gerson on Clinical Trial Accrual in MCL

May 12th 2020

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

May 12th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Smith on Safety Profiles of BTK Inhibitors in MCL

May 12th 2020

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Goy on Comparing the Toxicity Profiles of BTK Inhibitors in MCL

May 8th 2020

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Dr. Wang on the Results of the ZUMA-2 Trial in Relapsed/Refractory MCL

May 8th 2020

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision

May 7th 2020

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

May 5th 2020

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL

May 4th 2020

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.

MCL Treatments Step Away From Chemotherapy, Closer to a Cure

April 24th 2020

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.

Dr. Villa on the Use of BR as Induction Therapy in MCL

April 9th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).

CAR T-Cell Therapy KTE-X19 Makes Waves in Relapsed/Refractory MCL

April 9th 2020

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.

Dr. Goy on the Progression of MCL Treatment

April 8th 2020

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.